Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 19 | Angelidis-Smith MariaDirector | Grant or award | A | $300K 5,390 sh | Mar 12, 2026 |
| 19 | Nolf Aurelien Pierre LeonChief Financial Officer | Grant or award | A | — 779.0K sh | Mar 12, 2026 traded Mar 2, 2026 |
| 19 | Nanduru AnilSenior Vice President | Tax withholding | F | $298K 7,663 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 18 | Leshinski ScottPresident | Open-market sale · 10b5-1 plan | SELL | $176K 7,412 sh | Mar 12, 2026 traded Mar 11, 2026 |
| 17 | De Bosschere FabriceChief Accounting Officer | Tax withholding | F | $9,753 369 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Gallman CariEVP, General Counsel | Option exercise | M | — 5,201 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Caputo Richard L. Jr.SVP, Aerospace Systems | Option exercise | M | — 1,269 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Bennett Isham JayChief Human Resources Officer | Grant or award | A | — 39.1K sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | De Bosschere FabriceChief Accounting Officer | Option exercise | M | — 600 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Busque PhilippeSVP, GLOBAL SALES AND SERVICES | Option exercise | M | — 2,049 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Pittenger MaureenEVP, Chief HR Officer | Grant or award | A | — 816 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Fitzgerald Lindsay ClintonChief Public Affairs Officer | Open-market sale · 10b5-1 plan | SELL | $50K 20.0K sh | Mar 12, 2026 traded Mar 12, 2026 |
| 17 | De Bosschere FabriceChief Accounting Officer | Option exercise | M | — 158 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Burkhart ErinSVP, Controllership | Grant or award | A | — 2,355 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Fargis Edward CEVP & General Counsel | Grant or award | A | — 28.3K sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Hobbs Mark WayneEVP | Grant or award | A | — 4,715 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Duncan Thomas MichaelSVP, Chief Accounting Officer | Grant or award | A | — 5,439 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Checkovich Tennille J.Chief Legal Officer | Grant or award | A | — 28.4K sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Lenkowsky AdamEVP, Chief Commercial Officer | Option exercise | M | — 8,241 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Holzer Phil MSVP and Controller | Option exercise | M | — 4,612 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Grant or award | A | — 5,050 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Manchon PilarDirector | Disposition to issuer | D | — 30.5K sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Layton Kathleen I.Chief Legal Officer | Grant or award | A | — 70.4K sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Option exercise | M | — 1,246 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 17 | Hoch LynellePresident, Cell Therapy Org. | Option exercise | M | — 1,050 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Hoch LynellePresident, Cell Therapy Org. | Tax withholding | F | $55K 912 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Lenkowsky AdamEVP, Chief Commercial Officer | Tax withholding | F | $55K 913 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Holzer Phil MSVP and Controller | Other acquisition or disposition | J | — 2,264 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Holzer Phil MSVP and Controller | Tax withholding | F | $51K 849 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Knight Lea DanielsEVP & Chief Financial Officer | Tax withholding | F | $78K 8,089 sh | Mar 12, 2026 traded Mar 11, 2026 |
| 16 | Lenkowsky AdamEVP, Chief Commercial Officer | Tax withholding | F | $129K 2,146 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Pogosyan LianaChief Financial Officer | Tax withholding | F | $58K 28.1K sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Gallman CariEVP, General Counsel | Tax withholding | F | $81K 1,354 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Tax withholding | F | $90K 606 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 16 | Duncan Thomas MichaelSVP, Chief Accounting Officer | Disposition to issuer | D | $94K 1,326 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 15 | Vashisht RijuSenior Vice President | Tax withholding | F | $276K 7,080 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 14 | Schwartz LarissaSee Remarks | Open-market sale · 10b5-1 plan | SELL | $147K 1,836 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 13 | Hoch LynellePresident, Cell Therapy Org. | Option exercise | M | — 838 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 13 | Short Bartie WendyEVP, Corporate Affairs | Option exercise | M | — 749 sh | Mar 12, 2026 traded Mar 10, 2026 |
| 13 | Busque PhilippeSVP, GLOBAL SALES AND SERVICES | Option exercise | M | — 2,946 sh | Mar 12, 2026 traded Mar 10, 2026 |